A humanised Fc‐disabled immunoglobulin G1 monoclonal antibody against IL‐7Rα is also being evaluated for treating autoimmune diseases, with the anticipation that it will effectively block the actions of both TSLP and IL‐7.10 The gene discussed is IL7; the disease is autoimmune disease.